Zydus Lifesciences gets USFDA nod for diabetes drug
Business
Zydus Lifesciences just scored tentative approval from the USFDA for its Dapagliflozin Tablets, a generic version of Farxiga used to manage type 2 diabetes.
The drug comes in 5mg and 10mg doses and helps adults control blood sugar when paired with diet and exercise.
Drug pulled in over $10 billion in US sales
As per industry estimates, dapagliflozin had annual US sales of $10,486.9 million ( $10.49 billion).
Zydus makes these tablets at its Ahmedabad facility, and this approval adds to their already massive portfolio of 430 USFDA-approved products.
Zydus shares on Wednesday ended 0.23% up at ₹905 apiece on BSE.
Zydus received tentative approval for dapagliflozin in the US
Zydus received tentative approval for dapagliflozin in the US.
The company has recorded numerous USFDA approvals and ANDA filings.